HK1151727A1 - Combination therapy with antibody drug conjugates - Google Patents
Combination therapy with antibody drug conjugatesInfo
- Publication number
- HK1151727A1 HK1151727A1 HK11105912.1A HK11105912A HK1151727A1 HK 1151727 A1 HK1151727 A1 HK 1151727A1 HK 11105912 A HK11105912 A HK 11105912A HK 1151727 A1 HK1151727 A1 HK 1151727A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination therapy
- drug conjugates
- antibody drug
- antibody
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97959407P | 2007-10-12 | 2007-10-12 | |
| US2766808P | 2008-02-11 | 2008-02-11 | |
| US4064108P | 2008-03-28 | 2008-03-28 | |
| PCT/US2008/079224 WO2009048967A1 (en) | 2007-10-12 | 2008-10-08 | Combination therapy with antibody-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1151727A1 true HK1151727A1 (en) | 2012-02-10 |
Family
ID=40549535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11105912.1A HK1151727A1 (en) | 2007-10-12 | 2011-06-10 | Combination therapy with antibody drug conjugates |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8263083B2 (ru) |
| EP (1) | EP2211885B1 (ru) |
| JP (1) | JP5485897B2 (ru) |
| KR (1) | KR101641345B1 (ru) |
| CN (1) | CN101969970B (ru) |
| AU (1) | AU2008310908B2 (ru) |
| CA (1) | CA2699090C (ru) |
| EA (1) | EA020696B1 (ru) |
| HK (1) | HK1151727A1 (ru) |
| IL (1) | IL204851A (ru) |
| MX (1) | MX2010003977A (ru) |
| NZ (1) | NZ584552A (ru) |
| WO (1) | WO2009048967A1 (ru) |
| ZA (1) | ZA201002428B (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| ES2381788T3 (es) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| CN101969970B (zh) | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
| IL287292B (en) | 2008-01-31 | 2022-09-01 | Genentech Inc | and fusion antibody-drug-cd79b engineered antibodies cysteine- |
| CA2749115C (en) | 2009-01-09 | 2022-06-21 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| US8758758B1 (en) * | 2010-01-08 | 2014-06-24 | Seattle Genetics, Inc. | Post-relapse treatment of CD30 expressing lymphomas |
| EP2533804B1 (en) | 2010-02-08 | 2018-04-11 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
| TW202344270A (zh) * | 2010-09-29 | 2023-11-16 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
| US9272052B2 (en) | 2010-10-22 | 2016-03-01 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
| CN108152513B (zh) * | 2011-09-29 | 2020-07-24 | 西雅图基因公司 | 蛋白偶联的试剂化合物的整体分子量测定 |
| EP3309162A1 (en) * | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Targeted conjugates of pyrrolobenzodiazepines |
| US8828401B2 (en) | 2011-11-17 | 2014-09-09 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
| EP2812702B1 (en) * | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
| TW201726746A (zh) | 2012-11-07 | 2017-08-01 | 輝瑞股份有限公司 | 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體 |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| DK3160513T3 (da) | 2014-06-30 | 2020-04-06 | Glykos Finland Oy | Saccharidderivat af en toksisk payload og antistofkonjugater deraf |
| EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| AU2018347406A1 (en) * | 2017-10-11 | 2020-04-23 | Seagen Inc. | Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| US20200239585A1 (en) * | 2017-10-13 | 2020-07-30 | Seattle Genetics, Inc. | Modulating the immune response using antibody-drug conjugates |
| US20190343828A1 (en) * | 2018-04-06 | 2019-11-14 | Seattle Genetics, Inc. | Camptothecin peptide conjugates |
| WO2020127618A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic cd28 antigen binding molecules |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| CA3152316A1 (en) * | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| HUE057936T2 (hu) * | 2005-07-18 | 2022-06-28 | Seagen Inc | Béta-glükuronid-linker-hatóanyag konjugátumok |
| JP4860703B2 (ja) * | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | 最適化された抗ｃｄ３０抗体 |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008025020A2 (en) * | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
| WO2008103916A2 (en) | 2007-02-23 | 2008-08-28 | The Trustees Of Columbia Univeristy In The City Of New York | Compositions and methods for treating cancer or a neurotrophic disorder |
| CN101969970B (zh) | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
-
2008
- 2008-10-08 CN CN200880111297.1A patent/CN101969970B/zh active Active
- 2008-10-08 AU AU2008310908A patent/AU2008310908B2/en active Active
- 2008-10-08 WO PCT/US2008/079224 patent/WO2009048967A1/en active Application Filing
- 2008-10-08 JP JP2010529007A patent/JP5485897B2/ja active Active
- 2008-10-08 EP EP08837451.7A patent/EP2211885B1/en active Active
- 2008-10-08 CA CA2699090A patent/CA2699090C/en active Active
- 2008-10-08 EA EA201070463A patent/EA020696B1/ru unknown
- 2008-10-08 KR KR1020107008660A patent/KR101641345B1/ko active IP Right Grant
- 2008-10-08 NZ NZ584552A patent/NZ584552A/en unknown
- 2008-10-08 MX MX2010003977A patent/MX2010003977A/es active IP Right Grant
- 2008-10-08 US US12/681,599 patent/US8263083B2/en active Active
-
2010
- 2010-04-06 IL IL204851A patent/IL204851A/en active IP Right Grant
- 2010-04-07 ZA ZA2010/02428A patent/ZA201002428B/en unknown
-
2011
- 2011-06-10 HK HK11105912.1A patent/HK1151727A1/xx unknown
-
2012
- 2012-08-13 US US13/571,313 patent/US8470329B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5485897B2 (ja) | 2014-05-07 |
| KR20100087288A (ko) | 2010-08-04 |
| US20100215671A1 (en) | 2010-08-26 |
| EP2211885A1 (en) | 2010-08-04 |
| WO2009048967A1 (en) | 2009-04-16 |
| KR101641345B1 (ko) | 2016-07-20 |
| ZA201002428B (en) | 2011-06-29 |
| EA201070463A1 (ru) | 2010-10-29 |
| EA020696B1 (ru) | 2015-01-30 |
| CN101969970B (zh) | 2014-10-15 |
| NZ584552A (en) | 2012-07-27 |
| EP2211885A4 (en) | 2012-09-26 |
| IL204851A (en) | 2016-08-31 |
| IL204851A0 (en) | 2010-11-30 |
| US8263083B2 (en) | 2012-09-11 |
| JP2011500582A (ja) | 2011-01-06 |
| US8470329B2 (en) | 2013-06-25 |
| CA2699090C (en) | 2016-02-02 |
| US20130022627A1 (en) | 2013-01-24 |
| AU2008310908A1 (en) | 2009-04-16 |
| CN101969970A (zh) | 2011-02-09 |
| MX2010003977A (es) | 2010-04-30 |
| EP2211885B1 (en) | 2015-07-29 |
| AU2008310908B2 (en) | 2014-01-09 |
| CA2699090A1 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1151727A1 (en) | Combination therapy with antibody drug conjugates | |
| HK1207976A1 (en) | Auristatin drug linker conjugates | |
| PL1912671T3 (pl) | Koniugaty beta-glukuronid-linker-lek | |
| ZA201006763B (en) | Drug fusions and conjugates | |
| ZA201001442B (en) | Combination therapy with type i and type ii anti-cd20 antibodies | |
| EP2109625A4 (en) | USE OF ANTIBODY CONJUGATES | |
| EP2253348A4 (en) | DEVICE FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS | |
| EP2190853A4 (en) | HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID | |
| IL197316A0 (en) | Buprenophine-wafer for drug substitution therapy | |
| ZA201201218B (en) | 3-polylysine conjugates and the use thereof | |
| IL199992A0 (en) | Combination therapy | |
| EP1841467A4 (en) | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES | |
| EP2054061A4 (en) | COMBINATION THERAPY | |
| ZA200806318B (en) | Drug combinations | |
| GB0719518D0 (en) | Therapy | |
| ZA201003729B (en) | Conjugates of anti-rg-1 antibodies | |
| GB0815788D0 (en) | Therapeutic antibodies | |
| EP1838317A4 (en) | ANALGESIC CONJUGATES | |
| IL197883A0 (en) | Combination drug | |
| GB0700773D0 (en) | Drug therapies | |
| EP2076239A4 (en) | COMBINATION THERAPY | |
| GB0600528D0 (en) | Drug detector | |
| EP2211863A4 (en) | COMBINATION THERAPY | |
| IL199718A0 (en) | Peptide-complement conjugates | |
| EP2324059A4 (en) | THERAPEUTIC ANTI-PAMP ANTIBODIES |